Novo Nordisk is my top opportunity for 2026, driven by multiple catalysts and a compelling valuation. The Wegovy pill's FDA ...
Fortinet (FTNT) looks undervalued vs CrowdStrike, with a 2026 hardware refresh catalyst, strong profitability and buybacks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback